Sinocare Drives Global Academic Exchange and Innovations in Digital Diabetes Management

Recently, the Sinocare Diabetes Digital Management Conference (SDDMC), initiated and hosted by Sinocare, was successfully held in Shanghai. More than 110 top endocrinology experts and scholars from 24 countries gathered to engage in in-depth discussions on the deep integration of digital technology and diabetes management. Following the conference, the international delegation was invited to visit the headquarters of Sinocare Biosensing Co., Ltd. (Sinocare) in Changsha to conduct field research on China's innovative achievements and clinical practical experience in diabetes prevention and control.

SDDMC: A New Chapter in Comprehensive Full-Course Diabetes Management

On May 31, the international expert delegation participated throughout the entire agenda of the main venue and held a special seminar in the afternoon. Professor Juliana Chan from The Chinese University of Hong Kong chaired the meeting and pointed out: "We can utilize technologies, therapies, and data-driven approaches to turn crises into opportunities and prevent problems before they occur." This perspective resonated widely among the experts present, and several scholars shared the practical implementation and effectiveness of modern technology in diabetes management based on their respective national experiences.

Subsequently, Dr. Marijo Montales Laordin, an expert from the Philippines, presented a comparative analysis between the iCan i6 Continuous Glucose Monitoring (CGM) system and traditional blood glucose monitoring methods. She noted that the CGM group demonstrated superior efficacy in reducing glycated hemoglobin (HbA1c) levels. This finding not only validated the clinical advantages of continuous monitoring technology but also provided strong support for promoting data-centered, individualized diabetes management.

In the subsequent exchange, the participating experts conducted an in-depth seminar around CGM technology. The session featured presentations by four experts on CGM technology and its applications, exploring topics including the application of CGM technology in children with diabetes, the comparison between CCM (Corneal Confocal Microscopy) and CGM technologies, the application of CGM in intensive care, and the current status of patients with Type 1 diabetes. Following this, Ni Jiaying from Shanghai Sixth People's Hospital shared that among Type 2 diabetes patients not receiving insulin therapy, the application of CGM significantly improved HbA1c levels at 24 weeks compared to self-monitoring of blood glucose (SMBG). Russian expert Inna Vladimirovna Misnikova also stated that CGM has shown remarkable efficacy in the clinical practice of adult Type 1 diabetes. Multiple experts collectively expressed that CGM is becoming a vital tool for improving therapeutic outcomes and driving individualized precise management.

At the conclusion of the seminar, scholars from various countries engaged in a debate on the topic: "The development of artificial intelligence in diabetes diagnosis and treatment: Does it enhance or weaken doctors' core clinical decision-making capabilities?" This session fully stimulated the collision and deliberation of different perspectives, gathered the forward-looking insights of all experts, and provided a new dimension of thinking regarding the opportunities and challenges of artificial intelligence in diabetes management.

Visiting Sinocare Headquarters: Walking into a Chinese Brand, Witnessing Hardcore Technology

On June 4, the international delegation visited Sinocare’s Changsha headquarters to understand firsthand the innovative development of China's diabetes monitoring technology. The visit comprehensively demonstrated Sinocare's R&D capabilities and industrialization achievements in the field of blood glucose monitoring.

During the international exchange session, Ms. Li Xinyi, Vice Chairwoman and General Manager of Sinocare, engaged in an in-depth dialogue with global experts on global diabetes management trends. She shared Sinocare's technological evolution from finger-stick blood glucose testing equipment to its strategic layout in CGM, and explored the future trends of global diabetes management.

The delegation successively visited the Sinocare Diabetes Clinic, the Sinocare Corporate Exhibition Hall, and the automated production lines. At the clinic, the delegation experienced firsthand the efficient testing services of the "Sinocare Minute Clinic." The smooth process from information entry to obtaining the test report took only a few minutes, leaving a deep impression on the experts. In the exhibition hall, they learned about Sinocare's global layout through interactive displays, which clearly presented an international footprint with products exported to 187 countries and regions. In the production area, they inspected the automated production lines for blood glucose meters and test strips on-site; the highly integrated smart manufacturing system ensures product consistency and stability. Particularly in the CGM workshop at Sinocare's Qingshan Campus, the experts showed strong interest in Sinocare's self-developed CGM products, asking in detail about product performance and technical characteristics. On-site engineers answered core questions one by one regarding sensor accuracy, wear duration, and data calibration.

During the visit, several international experts positively evaluated Sinocare's R&D scale and manufacturing capacity. The international experts stated: "Sinocare's products ensure precision while maintaining a price advantage, which is of great significance for elevating the level of diabetes management in developing countries." Members of the delegation from various countries were deeply impressed by Sinocare's smart medical solutions, believing that this model is worthy of promotion in their home countries.

This visit built a platform for international mutual learning and exchange, showcasing the development achievements of China's diabetes management technology to the world, and laying the groundwork for future transnational collaborations. Relying on solid technical strength and a global vision, Sinocare has become an important participant and promoter of exchange in the international chronic disease management field.

Founded in 2002, Sinocare has deeply cultivated the fields of biosensing and digital chronic disease management, building a full-process diabetes management system based on the "Biosensing + AI + Healthcare" model. The company focuses on the independent R&D of core technologies such as CGM, winning multiple national-level industry honors, and constructing a complete business matrix covering testing, monitoring, and digital management. With highly accurate, cost-effective products and one-stop smart medical solutions, Sinocare’s business spans 187 countries and regions worldwide, benefiting over 25 million global users. Upholding its original intention to safeguard health, Sinocare will continuously break through technological boundaries, using dedicated products and professional services to protect the global population living with chronic diseases.